⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29494657 | 1.00 | — | — | |
| SCHEMBL9175196 | 1.00 | — | — | |
| SCHEMBL1649648 | 1.00 | — | — | |
| SCHEMBL25902 | 1.00 | — | — | |
| SCHEMBL11034701 | 1.00 | — | — | |
| SCHEMBL27620250 | 1.00 | — | — | |
| SCHEMBL28319254 | 1.00 | — | — | |
| SCHEMBL29872243 | 1.00 | — | — | |
| Iodide SCHEMBL10729245 | 0.71 | CA4 (0.33) | — | |
| Hydrochloric Acid SCHEMBL11141820 | 0.71 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121583592-A | Thorium-based molten salt reactor system with fuel salt and breeder salt isolated and operation method thereof | 上海核工程研究设计院股份有限公司 | 2026-02-27 | — | — | CN | claimed |
| US-12412677-B2 | Methods of energy generation from a Thorium molten salt system | TEXAS THORIUM LLC (US) | 2025-09-09 | — | — | US | claimed |
| CN-122071964-A | Air cooling supercritical carbon dioxide power generation system based on thorium-based molten salt reactor | 上海理工大学 | 2026-05-22 | — | — | CN | disclosed |
| US-20260084978-A1 | PROCESS FOR PRODUCING ATOMIC QUANTUM CLUSTERS DERIVATIVES | NANOGAP SUB NM POWDER S A (ES) | 2026-03-26 | — | — | US | disclosed |
| US-20260085064-A1 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2026-03-26 | — | — | US | disclosed |
| EP-4709424-A1 | LYOPHILIZED PRODUCTS, PHARMACEUTICAL COMPOSITIONS, AND KITS COMPRISING DYE-PEPTIDE CONJUGATES AND DERIVATIVES | Integro Theranostics, LLC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12577225-B2 | Nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2026-03-17 | — | — | US | disclosed |
| CN-121583592-A | Thorium-based molten salt reactor system with fuel salt and breeder salt isolated and operation method thereof | 上海核工程研究设计院股份有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20250339524-A1 | COMBINATION ANTI-4-1BB IMMUNOTHERAPY, RADIOTHERAPY, AND B CELL ACTIVATION THERAPY | H LEE MOFFITT CANCER CT & RES (US) | 2025-11-06 | — | — | US | disclosed |
| US-12412677-B2 | Methods of energy generation from a Thorium molten salt system | TEXAS THORIUM LLC (US) | 2025-09-09 | — | — | US | disclosed |
| US-12371420-B2 | Polymorphs of Selinexor | Karyopharm Therapeutics Inc. (US) | 2025-07-29 | — | — | US | disclosed |
| EP-3990042-A1 | OCULAR DEVICE DELIVERY METHODS AND SYSTEMS | Layerbio, Inc. (US) | 2022-05-04 | — | — | EP | disclosed |
| CN-108440515-B | Substituted benzofuranyl and benzoxazolyl compounds and uses thereof | 卡尔约药物治疗公司 | 2022-05-03 | — | — | CN | disclosed |
| US-11318120-B2 | Nuclear transport modulators and uses thereof | BIOGEN MA INC. (US) | 2022-05-03 | — | — | US | disclosed |
| CN-114340690-A | Ocular device delivery methods and systems | 雷尔生物公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220093282-A1 | Nuclear Power Generation using a Thorium Molten Salt Reactor with a Compact Thermal Neutron Generator | CHOI KYUNAM (US) | 2022-03-24 | — | — | US | disclosed |
| EP-3962498-A1 | COMBINATION THERAPIES | Memorial Sloan Kettering Cancer Center (US) | 2022-03-09 | — | — | EP | disclosed |
| US-20220054550-A1 | COMBINATION THERAPIES | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-02-24 | — | — | US | disclosed |
| WO-2022031925-A1 | ULTRA EFFICIENT ACCELERATOR PRODUCTION OF ISOTOPICALLY PURE ACTINIUM-225 | CRYORAD, INC. (US) | 2022-02-10 | — | — | WO | disclosed |
| CN-114025775-A | Combination therapy | 纪念斯隆-凯特琳癌症中心 | 2022-02-08 | — | — | CN | disclosed |